Retatrutide — 10mg
Original price was: $160.00.$120.00Current price is: $120.00.
Retatrutide is a multi-receptor peptide agonisttargeting GLP-1, GIP, and glucagon receptors, designed for advanced metabolic research.
It is under investigation for its effects on energy balance, glucose control, and body weight regulation, positioning it at the frontier of polypeptide-based research.
RIPLE-ACTION PEPTIDE
Three Receptors, One Molecule: Taking Dual Action One Step Further
Retatrutide goes beyond what dual-action peptides like Tirzepatide can do. Instead of activating two receptors, it targets three key receptors at once: GLP-1, GIP, and Glucagon. Think of it as having three keys that unlock three different doors simultaneously. This triple approach has been documented in published research for its effects on appetite, blood sugar, and how the body burns energy.
- Activates GLP-1, GIP, and Glucagon receptors together
- First compound designed with this triple mechanism
- One injection per week (lasts about 6 days in the body)
- Well-documented in peer-reviewed scientific journals
- Stable compound suitable for research protocols
For laboratory research use only. Not for human consumption.
THREE PATHWAYS WORKING TOGETHER
What Each Receptor Does — And Why Three Is Better Than Two
Each receptor in Retatrutide has a specific job. GLP-1 helps reduce appetite and slows down digestion. GIP improves how the body handles insulin and fat. The new addition — Glucagon — tells the body to burn more energy and break down stored fat. When all three work together, they create results that none could achieve alone. It’s like a team where each player has a unique skill.
- GLP-1: Reduces hunger and slows stomach emptying
- GIP: Helps with insulin and fat processing
- Glucagon: Increases energy burning and fat breakdown
- Together they create a “synergy” effect
- Combined results exceed what each could do separately
For laboratory research use only. Not for human consumption.
RESEARCH APPLICATIONS
What Researchers Are Studying with Retatrutide
Retatrutide has become a valuable tool for scientists exploring how the body manages energy, appetite, and metabolism. Because it affects three pathways at once, researchers can answer questions that were impossible before: How do these systems interact? What happens when all three are activated together? The scientific literature continues to grow with new findings.
- Blood sugar regulation and insulin response
- Energy burning and heat production (thermogenesis)
- Appetite signals and feeling of fullness
- How the body stores and breaks down fat
- Comparing single vs dual vs triple receptor effects
- Long-term studies with weekly dosing
For laboratory research use only. Not for human consumption.
Understanding Retatrutide: The Science Made Simple
Retatrutide represents the next step in metabolic research peptides. While Tirzepatide works on two receptors (GLP-1 and GIP), Retatrutide adds a third: the Glucagon receptor. This might sound like a small change, but it opens up entirely new possibilities for studying how the body manages energy.
Here’s how each receptor contributes: GLP-1 is like a “stop eating” signal — it reduces appetite and tells the stomach to empty more slowly. GIP helps the body handle insulin better and process fats more efficiently. Glucagon does something different: it tells the body to burn stored energy and increase heat production. Most peptides only use the first two — adding glucagon brings the energy-burning piece to the table.
Why does having all three matter? When these pathways work together, they create what scientists call synergy. The combined effect is greater than what you’d expect from adding up each individual effect. It’s like three musicians playing together creating something more powerful than three solo performances combined.
The compound stays active in the body for about 6 days, which means researchers can use a simple weekly schedule. For scientists studying metabolism, energy balance, or how appetite works, Retatrutide offers a unique way to see how these interconnected systems work as a team.
For research use only. Not for human consumption.
SCIENTIFIC LITERATURE
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. N Engl J Med. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Diabetes Obes Metab. 2022.
- Retatrutide. StatPearls Publishing; 2024.
CERTIFICATE
A detailed summary of the analytical profile, purity, and molecular integrity of the research-grade peptide compound.
DIRECTIONS
Be the first to review “Retatrutide — 10mg”
Related products
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Fat Loss
Reviews
There are no reviews yet.